31 research outputs found

    Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment

    Get PDF
    On 30 January 2020, the World Health Organization (WHO) declared the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic a public health emergency of international concern. The viral outbreak led in turn to an exponential growth of coronavirus disease 2019 (COVID-19) cases, that is, a multiorgan disease that has led to more than 6.3 million deaths worldwide, as of June 2022. There are currently few effective drugs approved for treatment of SARS-CoV-2/COVID-19 patients. Many of the compounds tested so far have been selected through a drug repurposing approach, that is, by identifying novel indications for drugs already approved for other conditions. We here present an up-to-date review of the main Food and Drug Administration (FDA)–approved drugs repurposed against SARS-CoV-2 infection, discussing their mechanism of action and their most important preclinical and clinical results. Reviewed compounds were chosen to privilege those that have been approved for use in SARS-CoV-2 patients or that have completed phase III clinical trials. Moreover, we also summarize the evidence on some novel and promising repurposed drugs in the pipeline. Finally, we discuss the current stage and possible steps toward the development of broadly effective drug combinations to suppress the onset or progression of COVID-19

    Magnet-Less Circulators Based on Spatiotemporal Modulation of Bandstop Filters in a Delta Topology

    No full text

    Broadband Cyclic-Symmetric Magnetless Circulators and Theoretical Bounds on Their Bandwidth

    No full text

    Trehalose Accumulation in Wheat Plant Promotes Sucrose and Starch Biosynthesis

    No full text
    Abstract Seeds of Triticum aestivum L. (cv. Sakha 93) were sown in pots and grown under controlled conditions in growth chamber. The plants were irrigated with half strength of Hoaglad solution without or with 10 or 30 ”M validamycin A, a potent inhibitor of trehalase. Plants were collected at three different stages of growth (17, 24 and 31 DAP). Validamycin A decreased the activity of trehalase which leads to the accumulation of trehalose in shoot and root of wheat plants. Raising trehalose level in the plant tissues was accompanied by increase in the sucrose content and starch content of the shoot. The increased contents in sucrose and starch were mainly attributed to the increased levels of trehalose. The effect of trehalose on the sucrose degrading enzymes (alkaline and acid invertases and sucrose synthase) showed stimulation of alkaline invertase activity and inhibition of acid invertase and sucrose synthase. The opposite behavior of sucrose degrading enzymes suggests a regulation mechanism controlling the sucrose pool
    corecore